全文获取类型
收费全文 | 627篇 |
免费 | 35篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 1篇 |
基础医学 | 41篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 164篇 |
皮肤病学 | 83篇 |
神经病学 | 8篇 |
特种医学 | 20篇 |
外科学 | 57篇 |
综合类 | 13篇 |
预防医学 | 7篇 |
眼科学 | 6篇 |
药学 | 11篇 |
肿瘤学 | 227篇 |
出版年
2023年 | 8篇 |
2022年 | 4篇 |
2021年 | 15篇 |
2020年 | 7篇 |
2019年 | 14篇 |
2018年 | 25篇 |
2017年 | 16篇 |
2016年 | 21篇 |
2015年 | 18篇 |
2014年 | 16篇 |
2013年 | 19篇 |
2012年 | 52篇 |
2011年 | 45篇 |
2010年 | 36篇 |
2009年 | 17篇 |
2008年 | 36篇 |
2007年 | 37篇 |
2006年 | 40篇 |
2005年 | 33篇 |
2004年 | 28篇 |
2003年 | 18篇 |
2002年 | 39篇 |
2001年 | 16篇 |
2000年 | 15篇 |
1999年 | 8篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 1篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有663条查询结果,搜索用时 15 毫秒
1.
2.
Kensei Tobinai 《Nihon rinsho. Japanese journal of clinical medicine》2002,60(1):95-99
CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes. Of the 11 eligible patients enrolled in the phase I study in Japan, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m2 x 4 weekly infusions. The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61% (37/61) and 46% (6/13), respectively. Rituximab is a novel, effective anti-lymphoma agent with acceptable toxicities. 相似文献
3.
Kensei Minoda 《眼科学报》1996,(1)
Purpose: To disclose the structure of visual pigment gene for a protanopia with specific variation.Methods: Exon 5 fragments of the red andgreen visual pigment genes from the protanopia with specific varnation as well as controls were amplified by poly-merase chain reaction (PCR). The PCR products were put through heteroduplex-SSCP analysis and PCR-RFLP (restriction fragement length polymorphism) analysis to clarify the specific variation. The specific variation of the exon 5 DNA fragment from the protanopia was identified by sequencing.Results: A novel 5'green-3'red hybrid gene fragment without the normal red and green visual pigment gene was discovered in the protanopia. He should only have a single visual pigment gene, 5'green-3'red hybrid gene, on his X chromosome. The fusion point is between codon 285 and codon 296 in exon 5. Conclusion : Unequal intragenic recombination may occur in exon 5 as well as its upstream. A 5'green-3'red hybrid gene may present independently on the X chromosome without ac 相似文献
4.
Photoreceptor differentiation of retinoblastoma: An electron microscopic study of 29 retinoblastomas
Yasuo Tajima Shigeru Munakata Yasuo Ishida Tohru Nakajima Isamu Sugano Koichi Nagao Kensei Minoda Yoichiro Kondo 《Pathology international》1994,44(12):837-843
Retinoblastomas exhibit a unique form of differentiation to produce cell elements similar to those seen in a photoreceptor cell. An ultrastructural study was performed on 29 cases of retinoblastoma to further clarify the cytologic characteristics of the tumor cells. The age of the retinoblastomas averaged 17.1 months and the tumor cells showing photo-receptor differentiation were demonstrated in 10 cases (35%). The findings were especially notable in retinoblastomas with Flexner-Wintersteiner rosette formation (seven cases, 28%). Similar photoreceptor differentiation was also evident in solid cell clusters without rosette formation (four cases, 14%). The presence of photoreceptor elements was assumed to be significantly frequent both in Flexner-Wintersteiner rosettes and in the solid cell clusters. The cell cytoplasm also showed proliferation of long mitochondria and microtubules, reflecting photoreceptor differentiation. The hereditary-type retinoblastoma showed more advanced cell differentiation than the non-hereditary type. Photoreceptor differentiated retinoblastoma showed rather indolent growth compared with the undifferentiated type, and the former can expect a curative treatment by operation. These observations provide additional findings of the biological nature of retinoblastomas. 相似文献
5.
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma 总被引:11,自引:0,他引:11
K. Tobinai Y. Kobayashi M. Narabayashi M. Ogura Y. Kagami Y. Morishima T. Ohtsu T. Igarashi Y. Sasaki T. Kinoshita T. Murate 《Annals of oncology》1998,9(5):527-534
Background: In clinical trials in the USA, IDEC-C2B8 (a mouse-humanchimeric anti-CD20 monoclonal antibody) has demonstrated high response rateswith only mild toxic effects in relapsed B-cell lymphoma at a dose of fourweekly 375 mg/m2 infusions. The aim of the present trial wasto determine whether or not this dose is practically applicable to Japanesepatients with relapsed B-cell lymphoma with respect to safety,pharmacokinetics and efficacy.Patients and methods: Patients with relapsed CD20+ B-cell lymphomareceived intravenous infusions of IDEC-C2B8 once a week for four weeks. Atotal of 12 patients (four at 250 mg/m2 and eight at 375mg/m2) were enrolled.Results: All 11 eligible patients treated with either dose leveltolerated IDEC-C2B8 well. Commonly observed adverse drug reactions weregrades 1 or 2 non-hematologic toxicities during the infusion, consistingmostly of flu-like symptoms and skin reactions. All of the observedhematologic toxicities were of grade 3 or less, and transient. A rapid andsustained B-cell decrease in peripheral blood was observed, but noinfectious episodes were encountered. Human anti-mouse and anti-chimericantibodies were not detected. Of the 11 eligible patients (eight withfollicular, two with diffuse large-cell and one with mantle cell lymphoma),two showed a complete response and five showed a partial response, and allof the seven responders had lymphoma with follicular histology. Apharmacokinetic analysis showed that the elimination half-life (T1/2) ofIDEC-C2B8 was 445 ± 361 hours, and that the serum antibody levelsincreased in parallel with the course of infusions, and in most patients wasstill measurable at three months.Conclusions: The dose of four weekly 375 mg/m2 infusionsof IDEC-C2B8 is safe and effective in Japanese patients with relapsed B-celllymphoma. Further studies evaluating IDEC-C2B8 are warranted. 相似文献
6.
Yosuke Ando Takahiro Hayashi Kaori Ito Eri Suzuki Naoyuki Mine Ayumi Miyamoto Miyuki Oya Hidezo Matsuda Ami Isaji Toru Nakanishi Kazuyoshi Imaizumi Tomoyuki Shibata Tatsuyoshi Okada Kazuo Sakurai Kensei Naito Ichiro Uyama Kenji Kawada Hiroshi Takahashi Shigeki Yamada 《Supportive care in cancer》2016,24(2):871-878
7.
8.
9.
Masanori Someya Masakazu Hori Kunihiko Tateoka Kensei Nakata Masaru Takagi Masato Saito Naoki Hirokawa Masato Hareyama Koh-ichi Sakata 《Journal of radiation research》2015,56(1):122-127
In patients undergoing radiotherapy for localized prostate cancer, dose–volume histograms and clinical variables were examined to search for correlations between radiation treatment planning parameters and late rectal bleeding. We analyzed 129 patients with localized prostate cancer who were managed from 2002 to 2010 at our institution. They were treated with 3D conformal radiation therapy (3D-CRT, 70 Gy/35 fractions, 55 patients) or intensity-modulated radiation therapy (IMRT, 76 Gy/38 fractions, 74 patients). All radiation treatment plans were retrospectively reconstructed, dose–volume histograms of the rectum were generated, and the doses delivered to the rectum were calculated. Time to rectal bleeding ranged from 9–53 months, with a median of 18.7 months. Of the 129 patients, 33 patients had Grade 1 bleeding and were treated with steroid suppositories, while 25 patients with Grade 2 bleeding received argon plasma laser coagulation therapy (APC). Three patients with Grade 3 bleeding required both APC and blood transfusion. The 5-year incidence rate of Grade 2 or 3 rectal bleeding was 21.8% for the 3D-CRT group and 21.6% for the IMRT group. Univariate analysis showed significant differences in the average values from V65 to V10 between Grades 0–1 and Grades 2–3. Multivariate analysis demonstrated that patients with V65 ≥ 17% had a significantly increased risk (P = 0.032) of Grade 2 or 3 rectal bleeding. Of the 28 patients of Grade 2 or 3 rectal bleeding, 17 patients (60.7%) were cured by a single session of APC, while the other 11 patients required two sessions. Thus, none of the patients had any further rectal bleeding after the second APC session. 相似文献